
Dx Deals: Abbott Closes Exact Sciences Acquisition, Takes Control of Cologuard Franchise
Biotech giant purchased the company for $21 billion, one of the largest deals in clinical lab history

Biotech giant purchased the company for $21 billion, one of the largest deals in clinical lab history

The flow cytometry assay costs a fraction of traditional invasive bone marrow testing

The test offers a 76 percent sensitivity to detection of stage 1 and stage 2 pancreatic cancers

A physics-based urine test shows early promise in detecting bladder cancer recurrence without invasive procedures

The skin-based test can be used on children as young as two days old